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abstract
Cervical cancer is one of the most common cancers among women worldwide, and approximately 85% of
new diagnoses occur in less-developed regions of the world. Global efforts in cervical cancer to date have
focusedon primary and secondary prevention strategies of humanpapillomavirus vaccination andcervical
cancer screening. Cervical cancer screening is effective to reduce the incidence of cervical cancer and
can result in diagnosis at earlier stages, but it will take time to realize its full impact. With expansion of
screening programs, there is nowagreater imperative to increase access to treatment forwomenwho have
cervical cancer, particularly in earlier stages of disease, when it is still curable. Resources for multi-
modality treatment can be limited—or even absent—in many less-developed regions of the world andmay
be associated with geographic, social, and financial barriers for the patient. However, there is evidence
that, in many cases, less-invasive and less–resource-intensive treatment options are still effective. To this
end, the National Comprehensive Cancer Network and American Society of Clinical Oncology have
published guideline adaptations for specific resource constraints, and research about more conservative
approaches to the treatment of cervical cancer continues. This review focuses on potential barriers and
challenges to provision of safe and effective treatment of early-stage cervical cancer in lower-resource
settings, and it suggests future directions for expansion of access to cervical cancer treatment around the
world.
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INTRODUCTION
Cervical cancer is the fourth most common cause
of cancer in women worldwide and the most
common cancer in women in eastern and middle
Africa. Approximately 85% of the 528,000 new
diagnoses of cervical cancer and 87% of the
266,000 deaths occur in less-developed regions
of the world.1 Because of improvements in ma-
ternal health, deaths as a result of cervical cancer
now outnumber those that are results of maternal
mortality inmost countries in Asia and Latin Amer-
ica and in some countries in Africa.2 Even with
increasing availability of cervical cancer screening
and vaccination around the world, prevalent oc-
currences will continue to be identified and to
warrant treatment. In screenedpopulations, great-
er than half of detected cancers diagnosed can be
stage I or II, when less-radical treatment strategies
are still an option.3,4 To address wide variations
in the availability of resource-intense and highly
technical interventions, such as radical surgery,
chemotherapy, and radiation therapy, the Na-
tional Comprehensive Cancer Network (NCCN)
andAmerican Society of Clinical Oncology (ASCO)
have published resource-stratified guidelines to
delineate appropriate care options for womenwith
cervical cancer. The objective of this review is to
discuss barriers and challenges to treatment al-
ternatives for early-stage cervical cancer—stages
IA1 to IIA1—in lower-resource settings. Because
many lower-resource settings are in Africa, this
article largely focuses on the situation there; how-
ever, many of the principles and issues we raise
also are applicable to many parts of Asia and Latin
America.
CERVICAL CANCER PREVENTION
Cervical cancer can be prevented with human
papillomavirus (HPV) vaccination and cervical
cancer screening. Primary prevention with the
HPV vaccine is expected to result in a significant
decrease in the incidence of cervical cancer
worldwide. Epidemiologic modeling has esti-
mated that vaccine coverage of 90%could result
in a decrease of up to 83% in incident cervical
cancer occurrencesworldwide.5TheHPVvaccine
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became available in 2006 and is available in
approximately one third of low- and middle-
income countries (LMICs), but many programs
in low-income countries reach less than 10% of
the target population.6 Although the vaccine is
promising, differences in cervical cancer inci-
dence that result from HPV vaccination will take
decades to be realized.
In the shorter term, secondary prevention with
cervical cancer screening has been shown to
prevent malignancy when precancer is detected
and treated. Furthermore, prevalent occurrences
of invasive cancer are detected at earlier stages. In
India, a cluster-randomized trial of 30,577women
compared a single round of visual inspection with
acetic acid (VIA)–based screening versus no
screening and found that, in the screened arm,
35% of cervical cancer occurrences were stage I,
and 18% were stage II, compared with 0% and
6%, respectively, in the control arm.3 Cytology is
the most commonly used screening method in
developedcountries, but see-and-treat VIA isused
frequently in lower-resource settings.7 Greater
than 50 low-income countries have introduced
cervical cancer screening with VIA.8
Although the availability of cervical cancer screen-
ing programs has been increasing, coverage is
still low. Most screening programs in low-income
countries and the WHO African region are esti-
mated to reach less than 10% of the population.6
Therefore, as screening programs scale, they
likely will continue to identify a large number of
prevalent invasive cancer occurrences that re-
quire treatment.
RESOURCE-STRATIFIED GUIDELINES FOR THE
TREATMENT OF CERVICAL CANCER
Cervical cancer is clinically, rather than surgi-
cally, staged via the International Federation
of Gynecology and Obstetrics (FIGO) system9
(Table 1). Treatment of early-stage invasive cer-
vical cancer historically has included surgery,
such as cold knife conization, simple hysterec-
tomy, or radical hysterectomy with pelvic lymph
node dissection.10,11 More advanced disease
generally is treated with chemoradiation.11,12
However, radical surgery, chemotherapy, and/
or radiation are not available inmany parts of the
world. They are expensive modalities and re-
quire highly trained personnel and quality as-
surance, whichmay not be realistic or feasible in
some locations. For example, surgical treatment
of locally advanced disease is typically a radical
hysterectomy, which, in contrast to a simple
hysterectomy, involves removal of parametrial
tissue and an additional vaginal margin. The
surgery is technically more difficult to perform,
requires more specialized training, and carries a
higher risk of operative (eg, bleeding, infection,
and injury) and long-term (eg, bladder dysfunc-
tion and fistula) complications. As a result, there
is increasing research on more conservative
approaches to the treatment of cervical can-
cer.13 In lower-resource settings, options such
as cold-knife conization, simple hysterectomy,
or neoadjuvant chemotherapy followed by sim-
ple hysterectomy may provide more realistic
options for cure.
The NCCN guidelines provide multiple options to
treat each cervical cancer stage (Table 2), includ-
ing options for fertility-sparing treatment in early
stages.11 Treatment of stage IA disease generally
is less invasive and can be adapted to lower-
resource settings. However, patients in lower-
resource settings are more likely to present at
stages for which the recommended treatmentmo-
dality is not readily available.14-16 Therefore, both
the NCCN (in the NCCN Framework) and ASCO
created resource-stratified guidelines for women
with invasive cervical cancer (Table 2).17,18 Both
guidelines outline recommendations for each of
four resource levels: basic, limited, enhanced,and
maximal. For example, althoughNCCNguidelines
recommend a radical hysterectomy with pelvic
lymph node dissection or chemoradiation with
brachytherapy for stage IB1 disease, the NCCN
Framework guidelines recommend a simple hys-
terectomy or radical hysterectomy with pelvic
lymph node dissection for basic-level settings;
ASCO recommends a simple hysterectomy with
or without neoadjuvant chemotherapy at that
same level.
RESOURCES CURRENTLY AVAILABLE IN
LOWER-RESOURCE SETTINGS
Surgery
Adequate training and access to appropriate pro-
viders have been ongoing limitations in global
health. Compared with high-income countries,
which have 28.7 physicians per 10,000 people,
low-income countries have only 2.5 physicians
per 10,000people.19 Low-incomecountrieshave
an estimated 0.7 surgical providers per 100,000
people compared with 56.9 in high-income
countries.20
There are fewer statistics on capacity for gyneco-
logic surgery. A review of the loop electrosurgical
excision procedure (LEEP) in lower-resource
countries found that this procedure usually is
performed by physicians.21 However, it is feasible
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to train nonphysicians to perform the procedure
safely, and such training may represent a task-
shifting opportunity. A program in Kisumu, Kenya,
has successfully trained and certified clinical of-
ficers (the equivalent of a physician assistant) to
perform LEEPs.22
Data about capacity to perform simple hysterec-
tomies, radical hysterectomies, and lymph node
dissections in lower-resource settings are scarce.
Many providers who currently perform hysterec-
tomies in lower-resource settings are primary
care physicians who have undergone only 1 year
of surgical training. Radical hysterectomy is not
available in many lower-resource settings or may
be available only in large central hospitals.23,24
Many professional societies and nongovernmen-
tal organizations have initiated independent
volunteer-based efforts in different countries to
expand this capacity through didactics and
hands-on mentorship in Africa, Central America,
and Asia.25-27 Although efforts by voluntary or-
ganizations to improve training of local providers
are laudable, formal teaching programs within
each country must be developed and supported
locally, either by providing in-country training or
by sending qualified candidates abroad.
Even when surgical services exist, they often are
concentrated in referral hospitals in urban areas,
which may result in barriers related to cost,28
transport, long wait times, poor referral networks,
and inability to pay. Patients also may be hesitant
to undergo surgery because of fear of the pro-
cedure, fear of anesthesia, and rumors of poor
outcomes.29 Even if trained surgical personnel
exist, surgical services may be intermittently avail-
able because of supply and medicine stockouts,
power shortages, inconsistent water supply, and
poor infrastructure.30
Radiation Therapy
There are inadequate personnel and equipment
to meet the demand for radiation therapy in
lower-resource settings.31 The worldwide stan-
dard for the number of radiation megavoltage
machines is one per 700,000 to 800,000 people
or per 350 to 400 patients with cancer.32 In a
recent survey of radiotherapy capacity, the av-
erage number of teletherapy machines per mil-
lion people was 0.21 for low-income countries
compared with 8.6 for high-income countries.33
Of the 52 African countries in this survey, only 23
offered external-beam radiotherapy, and only 20
offered brachytherapy. Combined, these coun-
tries housed 88 cobalt-60 units and 189 linear
accelerators; however, 60% of these machines
were concentrated in South Africa (n = 92 ma-
chines) and Egypt (n = 76 machines). Most
radiotherapy centers only provided basic ser-
vices, such as palliation and simple curative
treatments, on the basis of two-dimensional im-
aging and treatment planning.33 A separate sur-
vey of 17 countries in the Asia and Pacific region
reported 0.09 to 7.39megavoltagemachines per
million people.34 Only four countries—Australia,
Japan,NewZealand, andSingapore—exceeded
two machines per million people. In this survey,
many departments reported treatment of pa-
tients without simulators or treatment-planning
systems. Furthermore, radiation oncologists
often had additional duties, such as medical
Table 1. 2014 FIGO Staging for Cancer of the Cervix Uteri
Stage Description
I The carcinoma is strictly confined to the cervix (extension to the
uterine corpus should be disregarded).
IA Invasive cancer is identified only microscopically. Invasion is
limited tomeasured stromal invasion,with amaximumdepth
of 5 mm and a maximum width of 7 mm.
IA1 Measured invasion of stroma< 3 mm in depth and< 7 mm in
width
IA2 Measured invasionof stroma.3mmand,5mmindepthand
< 7 mm in width
IB Clinical lesions confined to the cervix, or preclinical lesions
greater than those defined as stage IA
IB1 Clinical lesions no greater than 4 cm in size
IB2 Clinical lesions . 4 cm in size
II The carcinoma extends beyond the uterus, but it has not
extended onto the pelvic wall or to the lower third of vagina.
IIA Involvement of up to the upper two thirds of the vagina; no
obvious parametrial involvement
IIA1 Clinically visible lesion < 4 cm
IIA2 Clinically visible lesion . 4 cm
IIB Obvious parametrial involvement but not onto the pelvic
sidewall
III The carcinomahas extended onto the pelvic sidewall. On rectal
examination, there is no cancer-free space between the
tumor and pelvic sidewall. The tumor involves the lower third
of the vagina.
IIIA Involvement of the lower vagina but no extension onto pelvic
sidewall
IIIB Extension onto the pelvic sidewall, or hydronephrosis/
nonfunctioning kidney
IV The carcinoma has extended beyond the true pelvis or has
clinically involved the mucosa of the bladder and/or rectum.
IVA Spread to adjacent pelvic organs
IVB Spread to distant organs
NOTE. Stages are defined in the FIGO Committee on Gynecologic Oncology: FIGO staging for carcinoma
of the vulva, cervix, and corpus uteri.9
Abbreviation: FIGO, International Federation of Gynecology and Obstetrics.
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oncology, medical physics, or diagnostic radi-
ology duties.34 In Latin America, the most re-
cent survey is from 2004 and identified 470
radiotherapy centers in the region, which had
710 machines across 19 countries. The dis-
tribution of centers ranged from none to 151
per country surveyed.31
Efforts to increase radiotherapy capacity in
lower-resource settings have been increas-
ing. The International Atomic Energy Agency
has been involved in projects to establish and
improve radiotherapy in countries around the
world.35 The International Education Subcom-
mittee of the American Society of Radiation
Oncology has collaborated with sister societies
around the world to foster education.36
Because of the complexity in the establishment of
safe infrastructure and the training of special-
ized teams that include radiation oncologists,
physicists, therapists, and nurses, radiotherapy
services likely will exist only in urban areas. In
addition to the difficulty of obtaining transport,
Table 2. Synthesis of Recommendations for Early-Stage Cervical Cancer by Stage and Use of Fertility-Sparing Approach
Stage
NCCN Guidelines11
NCCN Framework for
Resource Stratification17
ASCO Resource-Stratified
Clinical Practice Guideline18
Fertility Sparing Non–Fertility Sparing
Fertility
Sparing Non–Fertility Sparing
Fertility
Sparing Non–Fertility Sparing
IA1 (no
LVSI)
Cone biopsy Simple hysterectomy* Cone
biopsy
Simple hysterectomy* Cone
biopsy
Cone biopsy
OR
Simple hysterectomy
IA1 + LVSI,
or IA2
Cone biopsy + pelvic lymph
node dissection
Modified radical
hysterectomy + pelvic
lymph node dissection
Cone
biopsy
Simple hysterectomy Cone
biopsy
Cone biopsy
OR
OR OR OR Simple hysterectomy
Radical trachelectomy +
pelvic lymph node
dissection
Pelvic RT + brachytherapy Modified radical
hysterectomy
IB1 Radical trachelectomy +
pelvic lymph node
dissection
Radical hysterectomy +
pelvic lymph node
dissection
NA Simple hysterectomy +
pelvic lymph node
dissection
NA Simple hysterectomy
OR OR OR
Pelvic RT + brachytherapy Modified radical
hysterectomy + pelvic
lymph node dissection
NACT + simple
hysterectomy
IIA1 NA Radical hysterectomy +
pelvic lymph node
dissection
NA Simple hysterectomy +
pelvic lymph node
dissection
NA Simple hysterectomy
OR OR OR
Pelvic RT + brachytherapy Modified radical
hysterectomy + pelvic
lymph node dissection
NACT + simple
hysterectomy
IB2 NA Definitive pelvic RT +
concurrent cisplatin-
containing
chemotherapy +
brachytherapy
NA Radical hysterectomy +
pelvic lymph node
dissection
NA NACT + simple
hysterectomy
OR
OR
Simple hysterectomy (if
NACT not available)
Radical hysterectomy +
pelvic lymph node
dissection
Adjuvant chemotherapy
after hysterectomy if
histologic risk factors
present
NOTE. Recommendations in the NCCN Guidelines, the basic setting in the NCCN Framework for Resource Stratification of NCCNGuidelines for Cervical Cancer (2015), and the
basic setting in the ASCO Resource-Stratified Clinical Practice Guideline (2015) are compared.
Abbreviations: LVSI, lymphovascular space involvement; NA, not applicable; NACT, neoadjuvant chemotherapy; NCCN, National Comprehensive Cancer Network; RT, radiation
therapy.
*Cone biopsy with negative margins if not an operative candidate.
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patients may face barriers related to being away
from home for extended periods of time for their
course of radiotherapy. Radiotherapy also is
expensive—the capital costs of a linear accelera-
tor can be greater than 1million US dollars (USD),
and those of a cobalt machine can be up to
$480,000USD. Themedian annual cost of quality
assurance and maintenance of a linear accelera-
tor has been estimated as $41,000 USD; that of a
cobalt machine, $6,000 USD. These costs do not
include power, personnel, and building costs.37
Chemotherapy
In cervical cancer, chemotherapy can be used as
neoadjuvant therapy, as adjuvant therapy, or as a
sensitizing agent for radiation therapy. A recent
study about national essential medicine lists from
LMICs found that most lists contained multiple
oncology medicines.38 However, it is unclear how
this has translated into availability. Access likely is
limited: the African Palliative Care Association has
estimated that only 5% of patients with cancer
in Africa receive chemotherapy.39 In Southeast
Asia, an estimated 15% of patients from LMICs
in the region have access to essential oncology
medications.40
In addition to barriers, such as patient fear of
chemotherapy, distance from infusion centers,
andpoor referral networks, patients in LMICs likely
face difficulty with schedules and payments for
chemotherapy. A study in Cameroon found that
24% of patients experienced a delay in receipt
of chemotherapy because of finances, and 38%
were unable to schedule or keep a chemotherapy
appointment in a timely manner. A total of 40% of
patients spent greater than $200USD on themost
recent round of chemotherapy.41 This is a signif-
icant fraction of the gross national income per
capita of $1,026 USD to $4,035 USD that defines
the World Bank classification of lower and middle
income.42TheClintonHealthAccess Initiative and
American Cancer Society recognized cost as a
major obstacle to timely and high-quality cancer
care worldwide and established a partnership in
2015 to improve capacity for cancer treatment.
With an initial focus on breast and cervical cancer,
this initiative seeks to strengthen capacity at ter-
tiary hospitals and optimize the market for cancer
drugs (eg, chemotherapy) to expand access to
quality and affordable treatment.43
Pathology
Adequate pathology services are crucial to pro-
vision of oncology care, both to confirm malig-
nancy and to determine the best treatment. In
addition to human resource and training require-
ments for clinical pathologists and laboratory
technicians, sufficient infrastructure, equipment,
maintenance contracts, and reagents to properly
transport, fix, and process tissue for histologic
analysis are vital. In sub-Saharan Africa, there
are 84,133 to 9,264,500 people per pathologist,
which is a much higher ratio than the 15,000 to
20,000 people per pathologist in the United King-
dom or the United States. Of 30 sub-Saharan
African countries that reported data, immunohis-
tochemistry was available in 16 and molecular
diagnostics, in two.44 The scarcity of pathology
services may be due in part to the perception that
pathology services are restricted to services pro-
vided by laboratory technicians rather than by
medically trained clinicians.45
In 2014, the African Strategies for Advancing
Pathology group was created with the goal to
develop “a robust framework for efforts to in-
crease and improve pathology services within
sub-Saharan Africa.”44(p24) Other international
partners also are investing in improvements to
pathology capacity in lower-resource settings.46
Research Challenges
Many less-invasive treatment options for cervical
cancer, suchas those recommended in theNCCN
Framework and ASCO resource-stratified guide-
lines, are supported by small observational stud-
ies. Because of a lack of high-level evidence for
treatments feasible in more resource-limited set-
tings, many recommendations are based on ex-
pert consensus.17,18 Althoughmost of the disease
burden is in more resource-limited areas, cervical
cancer research is conducted disproportionately
in resource-rich settings. Therefore, a major chal-
lenge to extension of access to cervical cancer
treatment—particularly alternatives suitable for
resource-limited settings—is a strong evidence
base. Prospective studies with adequate sample
size and power to evaluate the efficacy and feasi-
bility of proposed treatment alternatives for early-
stagecervical cancer arenecessary. In the interim,
there is an urgency to start implementation of
innovative treatment strategies, because women
with potentially curable cancer continue to die
without any treatment.
Logistic and Social Challenges
It may take years to develop the human resources,
implement the systems of care, and procure the
supplies needed to provide the current resource-
intense standard of care for cervical cancer. Even
in settings where resources may be available,
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access continues to be a challenge, and poor
access can lead to delays in care and poorer out-
comes.47 For example, a study in New Delhi
reported a median of 41 days from registration to
radiation therapy initiation; 25% of patients did not
complete therapy.48ManyAfricancountries, includ-
ing Cameroon, Rwanda, and South Africa, have
reported an interval of up to 7 months between
request for care as a result of symptoms and treat-
ment of cancer.41,49,50 Although more than half of
the population in less-developed countries reside in
rural areas,51oncologyservices tend toexist inurban
areas. This means that many patients must travel
long distances for treatment and face competing
pressures amongcost of travel and treatment, family
obligations, and work responsibilities.
At the tertiary-care level, multidisciplinary manage-
ment will be essential to ensure continuity of care,
use of appropriate treatment protocols, and manage-
ment of adverse effects and complications from treat-
ment.Whenpatients present for care, systems should
be put in place to ensure that patients receive a timely
histologicdiagnosis,arenot lost tofollow-upbecauseof
confusionaboutmultiple treatmentmodalities, receive
referrals for adjuvant therapy in a timely manner, and
benefit from counseling to understand the nature of
the illness and the rationale for treatment.
Progress to Date
Although the literature is dominated by reports of
limitations in oncology services and barriers to
implementation, it is important to acknowledge
the progress that has been made. In 2012, the
African Organization for Research and Training in
Cancer launched the African Cancer Network
Project.Aspart of theproject, apartial list of cancer
treatment institutions in Africa was compiled and
included 102 centers.52 Some of these centers
may already be, or could become, research and
training hubs to help serve their regions, such as
Uganda, Bangladesh, and Rwanda.53
At a policy level, 79% of low-income countries and
84% of LMICs have a cancer policy, strategy, or
plan. Although only 45% and 58%, respectively,
have an operational policy with funding, the policy
efforts represent aspirations to improve oncology
services.54 Civil society is taking an active role
through community awareness, early detection
campaigns, and advocacy. Many efforts are survi-
vor led and focus on breast and cervical cancer.55
OPTIONS TO TREAT EARLY-STAGE CERVICAL
CANCER IN LOWER-RESOURCE SETTINGS
Early-stage cervical cancer spreads by local
extension to the endocervix, uterine corpus,
parametrium, and vagina. It also can spread via
lymphatic channels to the pelvic lymph nodes,
which confers a worse prognosis.56 This risk
serves as the rationale in higher-resource settings
for evaluation or treatment of the parametria and
pelvic lymph nodes with radical hysterectomy
and pelvic lymph node dissection in stages as
early as IA1 with lymphovascular space invasion
(LVSI). In a classic study of patients with stage I
disease treated with radical hysterectomy and
pelvic lymphadenectomy, tumor size, depth of
invasion, and LVSI were independent prognostic
factors for survival.57 The 3-year disease-free
survival (DFS) rate was 85.6% with negative
nodes and was 74.4% with positive nodes. DFS
in patients with positive parametria was 69.6%
and was 84.9% in patients with negative para-
metria. DFS was 69.1% in patients with positive
margins and was 84.3% in patients with negative
margins.57 Ideally, the goals of surgical therapy
are to excise tissue at risk for disease, achieve
negative margins, and determine the need for
additional therapy. Inwell-resourcedsettings, the
standard of care involves removal of any at-risk
areas, including the parametria and pelvic lymph
nodes; yet, many patients with early-stage dis-
ease do not have involvement of parametrium or
nodes and could theoretically be cured with less-
radical surgery. An increasing number of studies
haveprovidedevidence for less-radical surgery in
patients with stage IA2 and IB1 disease,58-60 in
whom the risk of parametrial involvement is ap-
proximately 2%and 6% to 10%, respectively and
the risk of pelvic lymph node metastases is less
than 15% (Table 3).61-64
LEEP
In theabsenceof other services, aLEEPprocedure
could be used in stages IA1, IA2, and IB1 disease
smaller than 2 centimeters. Studies of conserva-
tive treatment of stages IA1 to IB1 disease ranged
in eligibility criteria and use of adjuvant treatment
and may have included imaging modalities (eg,
magnetic resonance imaging) that are not readily
available in lower-resource settings.However, out-
comes from these studies suggest their feasibility.
An analysis of 1,409 patients with stage IA1 cer-
vical cancer reported a 5-year survival of 98%
versus 99% (hazard ratio, 0.65; 95% CI, 0.23 to
1.47) in women who underwent a cold knife con-
ization versus those who underwent a hysterec-
tomy.72 In IA2 disease, one study reported a 98%
survival rate in 66 women who underwent a cold
knife conization after a median follow-up time of
19 years. Twenty-eight of these patients under-
went lymphadenectomy, and no positive lymph
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nodes were identified.73 Maneo et al74 used cold
knife conization and pelvic lymph node dissection
to treat a selected group of patients with stage IB1
tumors smaller than 2 centimeters without evi-
dence of enlarged lymph nodes or uterine involve-
ment. After amedianof 66months, one recurrence
was noted 34 months after initial treatment. No
positive lymph nodes were found.74
Per theNCCNguidelines, a LEEP rather than a cold
knife conization is acceptable if specimen integrity
with adequate margins can be obtained. The pro-
cedure is relatively simple, canbedone in theclinic,
does not require a physician, and has established
feasibility and safety in LMICs.22,75,76 To study this
questionmore, twoprospectivestudies throughMD
Anderson Cancer Center and the Gynecologic On-
cology Group are underway to evaluate simple
hysterectomy or cone biopsy with pelvic lympha-
denectomy in early-stage cervical cancer.60,77
Neoadjuvant Chemotherapy
In larger tumors for which surgery may not be
sufficient or worthwhile without other treatment
modalities, neoadjuvant chemotherapy to re-
duce the tumor burden to enable surgical
excision can be considered. This approach is
recommended throughout the ASCO resource-
stratified guidelines.
One application for this approach could be neo-
adjuvant chemotherapy followed by a cold knife
conization, although theevidence is limited to small
studies of highly selected women, some of whom
ultimately underwent more radical surgery.78,79
Another application of neoadjuvant chemotherapy
couldbe to downstage the tumor inmoreadvanced
disease before a less radical surgery, such as a
simple hysterectomy. Few studies validate this
approach, and they typically are limited to the
fertility-sparing setting—for example, neoadjuvant
chemotherapy followed by laparoscopic lympha-
denectomy and vaginal simple trachelectomy.80
It is important to emphasize that neoadjuvant
chemotherapy currently is not standard treatment
and that the workup involved in determination of
eligibility, in itself, can involve resources that are
difficult to access in lower-resource settings. How-
ever, if resource-appropriate selection criteria can
be established, the number of patients who may
be able to obtain treatment would increase, par-
ticularly if more aggressive treatments are not
easily accessible.Ultimately, thechoiceof surgical
procedure should be tailored to the setting of each
patient and should be predicated onwhat surgical
care is safely available for the cancer stage of the
patient andwhether appropriate supplies, support
systems, and facilities are available.
FUTURE DIRECTIONS
The current global effort to prevent and detect
cervical cancer continues to scale. Screening pro-
grams ultimately will decrease cervical cancer
Table 3. Risk of Parametrial and Lymph Node Metastases by Stage
Stage Parametrial Involvement (%) Pelvic Lymph Node Metastases (%)
IA1 , 1 , 1
IA2 2 0-13
IB 15-20 9-20
IB1 6-10 Approximately 15
IIA 11-17 29-33
NOTE. Risks collated from published data.56,61-71
•  Develop local clinical protocols for care by using existing literature and international guidelines
•  Define safe and simple procedures to track patient safety during and after treatment
•  Establish minimal level of resources and supplies necessary to provide each treatment option (ie, pathology services,
   operating room backup, surgical/anesthesia backup)
•  Designate local and/or regional high-volume centers of excellence, where trained providers can provide high-volume
   high-quality care
Clinical care
•  Develop training program on staging, tumor burden assessment, indications for available treatment options
•  Continually evaluate time and resources necessary to acquire skills for management of early-stage cervical cancer
•  Establish credentialing/certification metrics for providers who treat patients with cervical cancer
•  Integrate basic competencies for identifying cervical cancer into medical school training
•  Embed training programs, including for procedures, in centers of excellence
Clinical
training
•  Compile quality assurance measures for pathology and gynecology to be overseen by local regulatory experts (ie, supply
   requirements, clinical volume for competency, outcomes assessment)
•  Strengthen tumor registries and patient-tracking systems to allow ongoing surveillance of patient outcomes
Quality
management
•  Provide ongoing training opportunities for aspiring investigators
•  Plan prospective studies to identify and evaluate treatment options appropriate for lower-resource settingsResearch
Fig 1. Future directions
to increase access to
cervical cancer treatment in
lower-resource settings
include attention to clinical
care, clinical training,
quality management, and
research.
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incidence after the initiation of screening and also
will downshift the stagedistributionof occurrences
if treatment becomes more widely available.3 As
awareness and advocacy about cervical cancer
increase, so does the imperative to provide access
to treatment. Inmany situations, the default often is
to do nothing, which means certain death. Some
resources are available, but they are not yet avail-
able to the same degree as in high-income econ-
omies. Doing nothing should not be an option;
therefore, researchers and policy makers should
focus their activities on howbest to balance the use
of existing resources with the expected impact on
quantity and quality of life (Fig 1). Clinicians should
use existing international guidelines, such as the
NCCN Framework and ASCO resource-stratified
guidelines, to provide the maximally feasible treat-
ment option. The medical and policy communities
shouldmeasure outcomes to ensure that goodcare
is being provided, identify areas for improvement,
and prioritize research activities. Future research
priorities in LMICs can focus on identification of
more resource-appropriate alternatives to the cur-
rent treatmentparadigmsandonstrategies tobetter
operationalize access to prevention and treatment.
In conclusion, although cervical cancer screen-
ing and prevention programs have been growing,
cervical cancer still is prevalent, and treatment
has not become widespread. Rather, women
often are referred to palliative care and are con-
demned to death. Although the traditional stan-
dard of care for early-stage cervical cancer has
been radical surgery or chemoradiation, there
are data to suggest less-invasive, and therefore
potentially more accessible, treatments. The
NCCN Framework and ASCO have published
resource-stratified guidelines with alternative
treatment recommendations that can guide coun-
tries in applications of their available resources to
cervical cancer treatment. For each patient, these
guidelines should be tailored to the extent of the
disease, the surgical procedures that can be
safely performed, and other available treatment
modalities. Although many gaps in oncology re-
sources and barriers to treatment exist, there is
increased political will and international attention
to improvingaccess to safe andeffective treatment
of cervical cancer.
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